T Mercier, V Desfontaine, S Cruchon, J A Da Silva Pereira Clara, M Briki, J Mazza-Stalder, A Kajkus, R Burger, V Suttels, T Buclin, O Opota, N Koehler, P M Sanchez Carballo, C Lange, P André, L A Decosterd, E Choong
OBJECTIVE: Anti-tuberculosis (antiTB) drugs are characterized by an important inter-interindividual pharmacokinetic variability poorly predictable from individual patients' characteristics. Therapeutic drug monitoring (TDM) may therefore be beneficial for patients with Mycobacterium tuberculosis infection, especially for the management of multidrug/extensively drug resistant- (MDR/XDR)-TB. Our objective was to develop robust HPLC-MS/MS methods for plasma quantification of 15 antiTB drugs and 2 metabolites, namely rifampicin, isoniazid plus N-acetyl-isoniazid, pyrazinamide, ethambutol (the conventional quadritherapy for susceptible TB) as well as combination of agents against MDR/XDR-TB: bedaquiline, clofazimine, delamanid and its metabolite M1, levofloxacin, linezolid, moxifloxacin, pretomanid, rifabutin, rifapentine, sutezolid, and cycloserine...
September 20, 2022: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences